ArticleFrontiers in immunology2025
Determination of the minimal level of neutralizing antibodies elicited following vaccination able to protect rabbits against virulent cowpox virus.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the diagnostic techniques and vaccine development of bovine herpesvirus types 1.Frontiers in veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serological assessment of antibody levels is a crucial measure of immunity in vaccinated animals. Establishing the level of antibodies considered protective is essential for vaccine standardization and evaluation of efficacy. The virus neutralization test (VNT), recognized as the gold standard for detecting virus-specific antibodies able to neutralize virus. Methods: This study evaluated the effect of viral dose on the detection of humoral immune responses in rabbits vaccinated with a cowpox virus-based vaccine. Blood serum samples were collected on days 14, 21, and 28 post-vaccination. VNT was conducted using viral doses of 100, 50, 25, and 10 TCID Results: Lower viral doses (25 and 10 TCID Conclusion: These results suggest that a low-dose (25 TCID
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.